Vascular endothelial growth factors and angiopoietins as new players in mastocytosis
Abstract Mastocytosis is a disorder characterized by the abnormal proliferation and/or accumulation of mast cells in different organs. More than 90% of patients with systemic mastocytosis have a gain-of-function mutation in codon 816 of the KIT receptor on mast cells (MCs). The symptoms of mastocytosis patients are related to the MC-derived mediators that exert local and distant effects. MCs produce angiogenic and lymphangiogenic factors, including vascular endothelial growth factors (VEGFs) and angiopoietins (ANGPTs). Serum concentrations of VEGF-A, VEGF-C, VEGF-D, ANGPT1 and ANGPT2 were determined in 64 mastocytosis patients and 64 healthy controls. Intracellular concentrations and spontaneous release of these mediators were evaluated in the mast cell lines $ ROSA^{KIT WT} $ and ROSA KIT D816V and in human lung mast cells (HLMCs). VEGF-A, ANGPT1, ANGPT2 and VEGF-C concentrations were higher in mastocytosis patients compared to controls. The VEGF-A, ANGPT2 and VEGF-C concentrations were correlated with the symptom severity. ANGPT1 concentrations were increased in all patients compared to controls. ANGPT2 levels were correlated with severity of clinical variants and with tryptase levels. VEGF-A, ANGPT1 and VEGF-C did not differ between indolent and advanced mastocytosis. $ ROSA^{KIT WT} $, $ ROSA^{KIT D816V} $ and HLMCs contained and spontaneously released VEGFs and ANGPTs. Serum concentrations of VEGFs and ANGPTs are altered in mastocytosis patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Clinical and experimental medicine - 21(2021), 3 vom: 09. März, Seite 415-427 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Marcella, Simone [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: | |
|---|---|
| Themen: |
Angiopoietins |
| Anmerkungen: |
© The Author(s) 2021 |
|---|
| doi: |
10.1007/s10238-021-00693-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR044505051 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR044505051 | ||
| 003 | DE-627 | ||
| 005 | 20230519190601.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210709s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10238-021-00693-0 |2 doi | |
| 035 | |a (DE-627)SPR044505051 | ||
| 035 | |a (SPR)s10238-021-00693-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.60 |2 bkl | ||
| 100 | 1 | |a Marcella, Simone |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vascular endothelial growth factors and angiopoietins as new players in mastocytosis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2021 | ||
| 520 | |a Abstract Mastocytosis is a disorder characterized by the abnormal proliferation and/or accumulation of mast cells in different organs. More than 90% of patients with systemic mastocytosis have a gain-of-function mutation in codon 816 of the KIT receptor on mast cells (MCs). The symptoms of mastocytosis patients are related to the MC-derived mediators that exert local and distant effects. MCs produce angiogenic and lymphangiogenic factors, including vascular endothelial growth factors (VEGFs) and angiopoietins (ANGPTs). Serum concentrations of VEGF-A, VEGF-C, VEGF-D, ANGPT1 and ANGPT2 were determined in 64 mastocytosis patients and 64 healthy controls. Intracellular concentrations and spontaneous release of these mediators were evaluated in the mast cell lines $ ROSA^{KIT WT} $ and ROSA KIT D816V and in human lung mast cells (HLMCs). VEGF-A, ANGPT1, ANGPT2 and VEGF-C concentrations were higher in mastocytosis patients compared to controls. The VEGF-A, ANGPT2 and VEGF-C concentrations were correlated with the symptom severity. ANGPT1 concentrations were increased in all patients compared to controls. ANGPT2 levels were correlated with severity of clinical variants and with tryptase levels. VEGF-A, ANGPT1 and VEGF-C did not differ between indolent and advanced mastocytosis. $ ROSA^{KIT WT} $, $ ROSA^{KIT D816V} $ and HLMCs contained and spontaneously released VEGFs and ANGPTs. Serum concentrations of VEGFs and ANGPTs are altered in mastocytosis patients. | ||
| 650 | 4 | |a Angiopoietins |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Mast cells |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Mastocytosis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Stem cell factor |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Tryptase |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Vascular endothelial growth factors |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Petraroli, Angelica |e verfasserin |4 aut | |
| 700 | 1 | |a Braile, Mariantonia |e verfasserin |4 aut | |
| 700 | 1 | |a Parente, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrara, Anne Lise |e verfasserin |4 aut | |
| 700 | 1 | |a Galdiero, Maria Rosaria |e verfasserin |4 aut | |
| 700 | 1 | |a Modestino, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Cristinziano, Leonardo |e verfasserin |4 aut | |
| 700 | 1 | |a Rossi, Francesca Wanda |e verfasserin |4 aut | |
| 700 | 1 | |a Varricchi, Gilda |e verfasserin |4 aut | |
| 700 | 1 | |a Triggiani, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a de Paulis, Amato |e verfasserin |4 aut | |
| 700 | 1 | |a Spadaro, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Loffredo, Stefania |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental medicine |d Milano : Springer, 2001 |g 21(2021), 3 vom: 09. März, Seite 415-427 |w (DE-627)SPR009227598 |w (DE-600)2054398-0 |x 1591-9528 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:3 |g day:09 |g month:03 |g pages:415-427 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10238-021-00693-0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.60 |q ASE |
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 3 |b 09 |c 03 |h 415-427 | ||